Boston Scientific

Advancing science for life™

TCT 2020
Investor Update

October 15th, 2020

Safe Harbor for Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans and product performance and impact, and the impact of the COVID-19 outbreak on the company's results of operations. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward looking statements.

Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Financial & Regulatory Disclaimers

Financial Disclaimers

Market Estimates: Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates.

Regulatory Disclaimers

SAVAL™ Drug-Eluting Below-the-knee Stent: U.S. Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.

Ranger™ Drug-Coated Balloon: CE Marked. U.S. Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.

Boston Scientific

Advancing science for life™

Peripheral Interventions

Jeff Mirviss

Executive Vice President and President, Peripheral Interventions

Michael R. Jaff, D.O.

Chief Medical Officer and Vice President of Clinical Affairs, Innovation and Technology, Peripheral Interventions

Category-leading Peripheral portfolio

Serves large & underpenetrated disease states

Arterial Disease
$3.2B Market, ~5% Growth

Peripheral Arterial Disease
Critical Limb Ischemia

ELUVIA™

SAVION™ Guidewires
SAVION FLX & SAVION DLVR

Category-leading balloon, stent, and wire portfolio

Jetstream™
Atherectomy

Peripheral Rotablator™



Ranger™

Venous Disease
$1.4B Market, ~8% Growth

Deep Venous Disease
Superficial Venous Insufficiency
Pulmonary Embolism

VICI VENOUS STENT®



AngioJet™
Thrombectomy

Sentry
Vena Cava Filter



Varithena
(polidocanol injectable foam) 1%
SVI Therapy

EKOS
Thrombolysis

Interventional Oncology
$1.6B Market, ~8% Growth

Cancer Therapies
(Liver, Kidney, Other)
Access & Delivery

TheraSphere®
Y90 Radiotherapy

Category-leading delivery & embolic portfolio

LCBead®
Embolization Beads

Cryoablation Therapy

$6B+ market: Category leadership & expanding into high-growth adjacencies

BTG acquisition update
Leveraging global footprint and significant synergies

Highly Complementary Portfolio

Interventional Oncology

Cancer Therapies + Access & Delivery


BTG | BSX

Venous Disease

Pulmonary Embolism + DVT


BTG | BSX

High-Growth Adjacencies

Pulmonary Embolism

~$0.5B oppty. by 2022

Superficial Venous Insufficiency

~$0.5B oppty. by 2022+

Cancer Therapies

$1B-$1.5B oppty. by 2022

Global Expansion

2019 Global Revenue Distribution



- Leveraging BSX global footprint
- Bringing legacy BTG technology to Asia Pacific

Significant Operational & Commercial Synergies

- Anticipate ~$175M in cost synergies by Aug 2022
  - Expect to realize 80% of the synergies by Aug 2021
- Multiple product launches and global regulatory approvals
- Cross-trained commercial teams
- Engaging customers as a combined entity

Robust product pipeline and launch cadence

Supports top tier growth

Boston Scientific

2020-2022E New Product Launches

Interventional Oncology

HEATfx™

Interventional Oncology Coils

TruSelect™

Venous Disease



CLOTHUNTER™

EKOS Thrombolysis

OptiCross 35™



Sentry Vena Cava Filter

Arterial Disease



Ranger™

Athletis™ PTA Balloon



Rubicon™ Control Support Catheter

Innovative pipeline + Geographic expansion

BSX drug-elution

Highly differentiated portfolio w/comparative evidence





Eluvia™
Drug-Eluting Vascular Stent

Eluvia's controlled release & polymer-based design make it unique:

- **Low Dose:** Polymer allows for lowest Ptx dose and sustained release
- **Durable Clinical Results:** especially in pts at high risk of restenosis – 24 month follow up

Ranger™
Drug-Coated Balloon

Designed to minimize downstream particulates while maximizing effectiveness:

- **Low Dose:** Designed to offer efficient drug transfer and low drug dose(2 µg/mm^2)
- **Competitive Clinical Results**
- **Trial Data: Only DCB with comparative data** – LINC 2020 presentation

Saval™
Drug-Eluting Stent

Only controlled drug release option for patients with below-the-knee disease:

- **Unmet Need:** Addresses significant unmet need in CLI patients via Breakthrough Pathway
- **U.S./EU launch targeted in 2022**

Medicare coverage and reimbursement update

Strengthened position and improved accessibility

ELUVIA™



EKOS Thrombolysis

Eluvia NTAP designation

CMS granted **New Technology Add-on Payment (NTAP)** for the Eluvia Drug-Eluting Vascular Stent System based on:

- Newness of the device
- Cost
- Substantial clinical improvement

NTAP payment is specific to Eluvia, not applicable to competitive products

EKOS reimbursement increase

EKOS ultrasound-assisted thrombolysis treatment reimbursement increased substantially

- 151% weighted average DRG payment increase for PE
- 204% weighted average DRG increase for peripheral vasculature

Boston Scientific

Advancing science for life™

Interventional Cardiology

Joe Fitzgerald
Executive Vice President and President, Interventional Cardiology
Dr. Ian Meredith, AM
Executive Vice President and Global Chief Medical Officer

Interventional Cardiology
Portfolio unmatched in depth and breadth



WATCHMAN FLX
LAAC



SYNERGY
XD, 48 mm,
MEGATRON
Drug-Eluting Stents

COMET II
Pressure Guidewire



ROTAPRO
Atherectomy

SENTINEL
Cerebral Embolic
Protection



LOTUS *Edge*
TAVR

ACURATE *neo2*
TAVR

Coronary Therapies

Innovation to accelerate our #1 global market share

Boston Scientific

SEE: PCI GUIDANCE

COMET™ II
Pressure Guidewire

AVVIGO™
Guidance System

OPTICROSS™ HD
Coronary Imaging
Catheter

PREPARE: CALCIUM TREATMENT

ROTAPRO™
Rotational
Atherectomy System

WOLVERINE™
Cutting Balloon

ROTAWIRE™ Drive
Atherectomy Wire

TREAT: DRUG-ELUTING THERAPIES

SYNERGY XD™ Stent
System (w/ 48mm)

SYNERGY MEGATRON™
Purpose-Built LV Stent

AGENT Drug-Coated
Balloon

Global footprint with integrated IVUS & FFR system to improve procedural decision-making & efficiency

Industry leader, proven standard of care with continued innovation

ROTAWIRE Drive Q1:21E

Unparalleled drug-eluting solutions with novel SYNERGY XD 48mm, SYNERGY MEGATRON & AGENT DCB

Structural Heart Valves

Driving category leadership with dual-valve strategy

SENTINEL

- Initiated the global Protected TAVR Clinical Trial in Q1:20
- Study randomizes ~3,000 patients 1:1 SENTINEL vs unprotected TAVR
- Enrolling at ~20 sites globally



LOTUS Edge

- Continued account expansion with over 250 accounts opened globally
- Provides complete control for optimal results even in the most complex patients
- REPRISE IV slower enrollment drives revised intermediate risk indication, now 2024E

ACURATE neo2

- ACURATE neo2 European launch underway
- 60% larger sealing skirt to minimize PVL
- Physicians cite intuitive implant & ease of deployment

Structural Heart Valves
SCOPE II results in context

Primary Endpoint (ITT & PP Analysis)



Aortic Regurgitation (PVL)



- Missed primary endpoint: composite of all-cause mortality or all stroke at 1 year
- Met non-inferiority in PP analysis but missed endpoint in ITT analysis
- While numerically better in disabling stroke, missed ITT due to higher rate of mortality
- Mortality differences possibly due to significant differences in Aortic Regurgitation (PVL)
- PVL known to be associated with increased mortality following TAVR

Structural Heart Valves
SCOPE II results in context (continued)

Powered Secondary Endpoint: New Pacemaker Implantation



Lowest pacemaker rates in self-expanding valves

- Key secondary endpoint, permanent pacemaker implantation, powered for superiority
- Confirmed superiority of ACURATE neo at 30 days and 1 year

Structural Heart Valves
ACURATE *neo2*

Next-Generation ACURATE neo2

ACURATE *neo*™ ACURATE *neo2*™



+60% larger outer sealing skirt

U.S. Timeline Update

FDA approval and U.S. launch in 2024E

ACURATE neo2 Benefits

- **Excellent procedural efficiency,** with short device usage time and high procedural success
- **Fast and more efficient TAVI,** with reduced length of stay and early discharge
- **Improved PVL**, with larger outer sealing skirt
- **Best in class pacemaker rates**
- **Outstanding hemodynamics with single-digit transvalvular gradients and large EOAs**
- **Straight-forward coronary access,** with large open cell frame design

WATCHMAN
Accelerating penetration and expanding addressable market

Boston Scientific

Estimated Global LAAC Market Size



Near Term Drivers
(2020 – 2024)

- **Strong market development** increasing **awareness** and bringing patients to therapy
- WATCHMAN **FLX** broadening patient **population** and accessing **new implanters**

Long Term Drivers
(2024 – 2026+)

- **Indication expansion** into lower bleeding risk patients through **CHAMPION-AF & OPTION** trials

WATCHMAN
Driving adoption with FLX and direct-to-patient outreach

PINNACLE FLX Performance

- **Efficacy:** 100% effective LAA closure at 12 months
- **Safety**: 0.5% adverse event rate
- **More anatomies**: Ability to treat broader range of LAA ostial ranges & depths

Patient Funnel

- Expanding on **excellent results** from 2019 national campaign
- High degree of **reach and frequency**
- Significant driver of **patient engagement**

Strong product pipeline
Supports future top tier growth

Boston Scientific

2020E

Peripheral Interventions
- Venous Wallstent indication – U.S.
- EKOS Controller 4.0
- Eluvia DES – China
- Ranger DCB SFA – U.S.
- Vici RDS stent
- AngioJet Clothunter
- HeatFX microwave ablation system
- TruSelect microcatheter

Coronary Therapies
- Comet II pressure wire
- SYNERGY XD w/ 48mm – U.S. and Japan
- SYNERGY High Bleeding Risk indication (HBR)- U.S.
- RotaPro – Japan
- AVVIGO FFR Guidance System

Structural Heart
- ACURATE neo2 (TAVR) – EU
- LOTUS Edge (TAVR) – Japan
- WATCHMAN FLX (LAAC) – U.S.

2021E

Peripheral Interventions
- Ranger DCB SFA – Japan
- OptiCross 35 IVUS Catheter
- Interventional Oncology Coils
- Athletis PTA Balloon

Coronary Therapies
- Megatron – U.S.
- SYNERGY XD – EU
- AVVIGO IVUS Guidance System
- ROTAWIRE Drive – U.S. Japan
- RotaPRO 2.0 - EU

Structural Heart
- ACURATE neo2 Global Expansion
- WM FLX U.S. Expansion
- WM FLX Japan

2022E

Peripheral Interventions
- SAVAL DES BTK – EU & U.S.
- Interventional Oncology Coils
- CLI Catheter

Coronary Therapies
- AVVIGO Prime Guidance System

Structural Heart
- WM FLX – China
- WM NG Sheath

Boston Scientific

Advancing science for life™

Q&A